



## PharmaMar announces the opening of a new affiliate in Austria

**Madrid, October 24th, 2016.** PharmaMar (MSE:PHM) has announced today the opening of a new affiliate in Austria with the aim of reinforcing the presence of the Company within Europe, one of the world's leading oncology markets.

As Luis Mora, Managing Director at PharmaMar's Oncology Business Unit, explains *"the opening of this affiliate is part of our growth strategy in certain European countries; this allows us to offer a better attention to our customers through our own teams. From Austria we can operate directly in Eastern European countries such as Poland and the Czech Republic"*.

With this new affiliate in Austria, PharmaMar now has a presence, with its own structure, in eight European countries. The other subsidiaries are located in Italy, Germany, France, Switzerland, Spain, the United Kingdom and Belgium consolidating the Company's business and distribution model.

### **The incidence of cancer in Austria**

According to GLOBOCAN<sup>i</sup> data, in 2012 41,100 new cases of cancer were detected in Austria. It is estimated that the risk of suffering cancer before the age of 75 is 30% in men and 22% in women. Prostate, breast and colorectal cancer are the most frequent types of tumor in Austria.

### **About PharmaMar**

Headquartered in Madrid, PharmaMar is a world-leading biopharmaceutical company in the discovery and development of innovative marine-derived anticancer drugs. The company has an important pipeline of drug candidates and a robust R&D oncology program. PharmaMar develops and commercializes YONDELIS<sup>®</sup> in Europe and has three other clinical-stage programs under development for several types of solid and hematological cancers, PM1183, plitidepsin, and PM184. PharmaMar is a global biopharmaceutical company with subsidiaries in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. PharmaMar fully owns other companies: GENOMICA, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and two other chemical enterprises, Zelnova Zeltia and Xylazel. To learn more about PharmaMar, please visit us at [www.pharmamar.com](http://www.pharmamar.com).

**Disclaimer**

This document is a press release, not a prospectus. This document does not constitute or form part of an offering or invitation to sell or a solicitation to purchase, offer or subscribe shares of the company. Moreover, no reliance should be placed upon this document for any investment decision or contract and it does not constitute a recommendation of any type with regard to the shares of the company.

**Media inquiries:**

Paula Fernández – Media Relations Manager  
[pfalarcon@pharmamar.com](mailto:pfalarcon@pharmamar.com)

Mobile: +34 638796215

Phone +34 918466000

**Investor Relations:**

Phone: +34 914444500  
Or visit our website  
[www.pharmamar.com](http://www.pharmamar.com)



---

<sup>i</sup> [http://globocan.iarc.fr/Pages/fact\\_sheets\\_population.aspx#](http://globocan.iarc.fr/Pages/fact_sheets_population.aspx#)